Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche and I-Mab form collaboration to study Tecentriq/TJD5 combination

Executive Summary

I-Mab Biopharma agreed to combine its anti-CD73 bispecific antibody TJD5 with Roche’s PD-L1 antagonist Tecentriq (atezolizumab) in a Phase I trial of patients with advanced or metastatic solid tumors who are refractory to or intolerant to all available therapy. The partners will share rights generated by the alliance.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations
    • R&D (No Licensing)

Related Companies